Medigene AG
MDG1
Company Profile
Business description
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
Contact
Lochhamer Strasse 11
Martinsried
PlaneggBY82152
DEUT: +49 892000330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
87
Stocks News & Analysis
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
stocks
Chart of the week: Did ASX companies underwhelm or impress during earnings season?
The Chart of the Week looks at how our Fair Values changes for Australian companies during earnings season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,966.60 | 136.80 | -1.69% |
| CAC 40 | 7,938.21 | 50.75 | -0.64% |
| DAX 40 | 22,567.14 | 109.27 | -0.48% |
| Dow JONES (US) | 40,724.45 | 626.48 | -1.52% |
| FTSE 100 | 8,542.56 | 46.57 | 0.55% |
| HKSE | 23,462.65 | 319.49 | -1.34% |
| NASDAQ | 17,255.43 | 393.02 | -2.23% |
| Nikkei 225 | 36,790.03 | 3.08 | -0.01% |
| NZX 50 Index | 12,209.05 | 201.92 | -1.63% |
| S&P 500 | 5,509.98 | 89.32 | -1.60% |
| S&P/ASX 200 | 7,749.10 | 141.00 | -1.79% |
| SSE Composite Index | 3,358.73 | 13.20 | -0.39% |